eMedicine Specialties > Psychiatry > Adult

Panic Disorder

Author: Colin Y Daniels, MD, Consulting Staff, Department of Psychiatry, Madigan Army MedicalCenter
Contributor Information and Disclosures

Updated: Apr 13, 2006

Introduction

Background

Panic disorder is characterized by the spontaneous and unexpected occurrence of panic attacks, the frequency of which can vary from several attacks a day to only a few attacks a year.

To meet the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for panic disorder, panic attacks must be associated with more than 1 month of subsequent persistent worry about (1) having another attack, (2) consequences of the attack, or (3) significant behavioral changes related to the attack.

Panic attacks are a period of intense fear in which 4 of 13 defined symptoms develop abruptly and peak rapidly less than 10 minutes from symptom onset. To make the diagnosis of panic disorder, panic attacks cannot directly or physiologically result from substance use, medical conditions, or another psychiatric disorder.

The DSM-IV-TR delineates the following potential symptom manifestations of a panic attack:

  • Palpitations, pounding heart, or accelerated heart rate
  • Sweating
  • Trembling or shaking
  • Sense of shortness of breath or smothering
  • Feeling of choking
  • Chest pain or discomfort
  • Nausea or abdominal distress
  • Feeling dizzy, unsteady, lightheaded, or faint
  • Derealization or depersonalization (feeling detached from oneself)
  • Fear of losing control or going crazy
  • Fear of dying
  • Numbness or tingling sensations
  • Chills or hot flashes

Panic disorder is usually qualified with the presence or absence of agoraphobia. Agoraphobia is defined as anxiety toward places or situations in which escape may be difficult or embarrassing. These anxiety-provoking situations are avoided or are endured with anxiety. (Note: Agoraphobia is not a stand-alone disorder; it is a descriptive term [eg, panic disorder with agoraphobia.])

Pathophysiology

Several non–mutually exclusive theories have been proposed to explain panic disorder, particularly from a biologic perspective, in response to the observed efficacy of certain pharmacologic agents for controlling the symptoms.

  • The serotonergic model suggests an exaggerated postsynaptic receptor response to synaptic serotonin. Recent studies report subsensitivity of 5HT1A receptors. The 5HT system or one of its subsystems may play a role in the pathophysiology of panic disorder, the precise nature of which must be delineated by further investigation.
  • The catecholamine model postulates increased sensitivity to adrenergic CNS discharges, with hypersensitivity of presynaptic alpha-2 receptors.
  • Similarly, the locus ceruleus model explains that panic symptoms are due to increased local discharge resulting in adrenergic neuron stimulation, similar to the more general catecholamine theory. Locus ceruleus activity also affects the hypothalamic-pituitary-adrenal axis, which can respond abnormally to clonidine in patients with panic disorder.
  • The lactate model focuses on symptom production by postulated aberrant metabolic activity induced by lactate.
  • The false suffocation carbon dioxide hypothesis explains panic phenomena by hypersensitive brainstem receptors.
  • The GABA model postulates decreased inhibitory receptor sensitivity, with a resultant excitatory effect.
  • The neuroanatomic model suggests that panic attacks are mediated by a "fear network" in the brain that involves the amygdala, the hypothalamus, and the brainstem centers.
  • The genetic hypothesis has attempted to refer panic disorder to definable genetic loci, without success to date.

Frequency

United States

Lifetime prevalence estimates range from 1.5-5% for panic disorder and 3-5.6% for panic attacks.

Mortality/Morbidity

Significant comorbidities are associated with panic disorder.

  • Panic disorder often coexists with mood disorders, with mood symptoms potentially following the onset of panic attacks. Lifetime prevalence rates of major depression may be as much as 50-60%. These patients may be at higher risk of suicide attempts. Alcohol and other substance use disorders are also frequent sequelae of panic disorder.
  • Medical conditions apparently share significant comorbidity with panic disorder. These conditions include cardiovascular disorders (eg, mitral valve prolapse, hypertension, cardiomyopathy) and other disorders (eg, chronic obstructive pulmonary disorder, irritable bowel syndrome, migraine headache).
  • Aside from the significant psychological anguish of panic attacks, agoraphobia can result in numerous medical, social, and occupational consequences. These include increased health care use, social withdrawal and restricted role functioning, and decreased work productivity.

Race

Data on prevalence in different racial groups are inconsistent. Symptom manifestations may differ, with African Americans more often presenting with somatic symptoms and more likely seeking help in medical rather than psychiatric settings.

Sex

One-month prevalence estimates for women are 0.7% versus 0.3% for men (ie, women are more likely to be affected than men by a 2- to 3-fold factor).

Age

Panic disorder has a bimodal distribution, with highest incidence in late adolescence and a second peak in the mid 30s.

Clinical

History

A sudden onset of a panic attack reportedly occurs with 4 (or more) of the 13 associated symptoms progressing to a peak within 10 minutes. Triggers and patterns help construct the differential diagnosis.

  • Unexpected panic attacks have no known precipitating cue; these panic attacks often support the diagnosis of panic disorder without agoraphobia.
  • Situationally bound (cued) panic attacks recur predictably in temporal relationship to the trigger; these panic attacks usually implicate a specific phobia-type diagnosis.
  • Situationally predisposed panic attacks are more likely to occur in relation to a given trigger, but they do not always occur. This pattern more likely describes panic disorder with agoraphobia.
  • Use of caffeine, alcohol, nicotine, or other substances can trigger or potentiate panic attacks.

Physical

No signs on physical or mental status examination are specific for panic disorder. The diagnosis is made primarily by history.

  • If the patient presents in an acute state of panic, he or she can physically manifest any anticipated sign of an increased sympathetic state. These nonspecific signs may include hypertension, tachycardia, mild tachypnea, and mild tremors. The attack lasts 20-30 minutes from onset—rarely more than an hour. Somatic concerns of death from cardiac or respiratory problems may be a major focus of patients during an attack. Patients may end up in an emergency department.
  • The Mental Status Examination may reveal an anxious-appearing person, although this is not required for diagnosis. Speech may reflect anxiety or urgency, or it may sound normal. Mood may be described as similar to "anxious," with congruent affect. Incongruent affect should raise consideration for other diagnostic possibilities. Thought processes should be logical, linear, and goal directed. Thought content is particularly important to specifically assess in order to ensure a patient has no suicidal or homicidal thoughts. Acute anxiety, as a form of acute mental anguish, can lead to unsafe behavior, usually directed against the self. Abnormalities in thought process or thought content (aside from impulsive suicidal thoughts) should prompt reconsideration of other etiologies. Insight and judgment are usually present and intact.

Causes

Panic disorder has moderate heritability, with heritability rates estimated to range from 0.3-0.6%. Segregation analyses have been inconclusive, and no distinct DNA linkages are known.

More on Panic Disorder

Overview: Panic Disorder
Differential Diagnoses & Workup: Panic Disorder
Treatment & Medication: Panic Disorder
Follow-up: Panic Disorder
References

References

  1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Press;2000.

  2. American Psychiatric Association. Practice guideline for the treatment of patients with panic disorder. Work Group on Panic Disorder. Am J Psychiatry. May 1998;155(5 Suppl):1-34. [Medline].

  3. Bandelow B, Behnke K, Lenoir S, et al. Sertraline versus paroxetine in the treatment of panic disorder: an acute, double-blind noninferiority comparison. J Clin Psychiatry. Mar 2004;65(3):405-13. [Medline].

  4. Fogel BS, Schiffer RB, Rao SM, eds. Neuropsychiatry. 1st ed. Baltimore, Md: Williams & Wilkins; 1996:. 263-8.

  5. Hales RE, Yudofsky SC, Talbott JA, eds. APA Textbook of Psychiatry. 3rd ed. Washington, DC: American Psychiatric Press; 1999.

  6. Kaplan HI, Sadock BJ, eds. Synopsis of Psychiatry. Behavioral Sciences/Clinical Psychiatry. 8th ed. Baltimore, Md: Williams & Wilkins; 1997:. 594-603.

  7. Pollack MH, Simon NM, Worthington JJ, et al. Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder. J Psychopharmacol. Sep 2003;17(3):276-82. [Medline].

  8. Sadock BJ, Sadock VA, Kaplan HI. Kaplan and Sadock's Comprehensive Textbook of Psychiatry. Baltimore, Md: Williams & Wilkins; 2000:. 1445-90.

  9. Stahl SM, Gergel I, Li D. Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. Nov 2003;64(11):1322-7. [Medline].

  10. Swoboda H, Amering M, Windhaber J, Katschnig H. The long-term course of panic disorder--an 11 year follow-up. J Anxiety Disord. 2003;17(2):223-32. [Medline].

Further Reading

Keywords

anxiety attack, panic attack, mood disorder, agoraphobia, phobia, anxiety disorder, anxiety provocation, acute anxiety, panic, panic disorder

Contributor Information and Disclosures

Author

Colin Y Daniels, MD, Consulting Staff, Department of Psychiatry, Madigan Army MedicalCenter
Colin Y Daniels, MD is a member of the following medical societies: American College of Physicians-American Society of Internal Medicine
Disclosure: Nothing to disclose.

Medical Editor

Mohammed A Memon, MD, Medical Director of Geriatric Psychiatry, Department of Psychiatry, Spartanburg Regional Hospital System
Mohammed A Memon, MD is a member of the following medical societies: American Association for Geriatric Psychiatry, American Medical Association, and American Psychiatric Association
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Iqbal Ahmed, MBBS, Professor, Department of Psychiatry, John A Burns School of Medicine, University of Hawaii
Iqbal Ahmed, MBBS is a member of the following medical societies: Academy of Psychosomatic Medicine, American Association for Geriatric Psychiatry, American Neuropsychiatric Association, and American Psychiatric Association
Disclosure: Nothing to disclose.

CME Editor

Harold H Harsch, MD, Program Director of Geropsychiatry, Department of Geriatrics/Gerontology, Associate Professor, Department of Psychiatry and Department of Medicine, Froedtert Hospital, Medical College of Wisconsin
Harold H Harsch, MD is a member of the following medical societies: American Psychiatric Association
Disclosure: lilly Honoraria Speaking and teaching; BMS Honoraria Speaking and teaching; Forest Labs Honoraria Speaking and teaching; AstraZeneca Honoraria Speaking and teaching; Pfizer Grant/research funds Other; Northstar Grant/research funds Other; Novartis  Other; Pfizer Honoraria Speaking and teaching

Chief Editor

Stephen Soreff, MD, President of Education Initiatives, Nottingham, NH; Faculty, Metropolitan College of Boston University, Boston, MA
Stephen Soreff, MD is a member of the following medical societies: American College of Mental Health Administration and American Psychosomatic Society
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.